Relationship between Serum IL-6，Cys C，and TNF-α and Sarcopenia in Patients with Chronic Kidney Disease and Its Impact on Patient Mortality Risk

Yutao WANG; Juan LIU

doi:10.12259/j.issn.2095-610X.S20241013

Volume 45 Issue 10

Oct. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(10): 85-90

Yutao WANG, Juan LIU. Relationship between Serum IL-6，Cys C，and TNF-α and Sarcopenia in Patients with Chronic Kidney Disease and Its Impact on Patient Mortality Risk[J]. Journal of Kunming Medical University, 2024, 45(10): 85-90. doi: 10.12259/j.issn.2095-610X.S20241013

Citation:

Yutao WANG, Juan LIU. Relationship between Serum IL-6，Cys C，and TNF-α and Sarcopenia in Patients with Chronic Kidney Disease and Its Impact on Patient Mortality Risk[J]. Journal of Kunming Medical University, 2024, 45(10): 85-90. doi: 10.12259/j.issn.2095-610X.S20241013

Citation:

PDF( 633 KB)

Relationship between Serum IL-6，Cys C，and TNF-α and Sarcopenia in Patients with Chronic Kidney Disease and Its Impact on Patient Mortality Risk

doi: 10.12259/j.issn.2095-610X.S20241013

Yutao WANG^{1, 2},
Juan LIU^{1
,
,}

1.
Dept. of Nephrology，Jiangyan Hospital of Traditional Chinese Medicine
2.
Hemodialysis Room，Taizhou Jiangsu 225500，China

Received Date: 2024-08-01
Available Online: 2024-10-15
Publish Date: 2024-10-31

Abstract

Abstract

Objective To investigate the relationship between serum interleukin-6 （IL-6）, cystatin C （Cys C）, tumor necrosis factor-α （TNF-α） and sarcopenia in patients with chronic kidney disease （CKD）, and its impact on mortality risk. Methods A retrospective study was conducted on the clinical data of 105 CKD patients undergoing maintenance hemodialysis （MHD） in a hospital from July 2019 to June 2021. The patients were divided into two groups based on whether they had sarcopenia during MHD, namely the sarcopenia group （n = 27） and the non- sarcopenia group （n = 78）. The clinical data of the two groups were compared, and the correlation between serum IL-6, Cys C, TNF-α levels and human data such as SMI and HGS was analyzed. The relationship between serum IL-6, Cys C, TNF-α and sarcopenia during MHD in CKD patients was analyzed, and the survival of CKD MHD patients was analyzed. And The effects of serum levels of IL-6, CysC, and TNF-α on the risk of death in patients with CKD were evaluated. Results In the sarcopenia group, SMI, HGS, and GS were all lower than in the non-sarcopenia group, while serum levels of IL-6, Cys C, and TNF-α were higher （P < 0.05）. In sarcopenia patients, serum IL-6, Cys C, and TNF-α levels showed a negative correlation with SMI, HGS, and GS （P < 0.05）. Elevated levels of serum IL-6, Cys C, and TNF-α were associated with the occurrence of sarcopenia in CKD patients during MHD （P < 0.05）. As serum levels of IL-6, Cys C, and TNF-α increased, the risk of developing sarcopenia during MHD in CKD patients gradually rose （P < 0.05）, and when serum levels of IL-6, Cys C, and TNF-α were high, the risk of death for CKD patients was 9.900 times, 10.688 times, and 4.936 times higher, respectively, compared to low levels. Conclusion In CKD patients, higher pre-MHD serum levels of IL-6, Cys C, and TNF-α are related to the occurrence of sarcopenia. Testing all three levels together can be used to assess the mortality risk in patients with muscle loss.
- CKD,
- MHD,
- Sarcopenia,
- Interleukin-6,
- Cystatin C,
- Tumor necrosis factor-α

FullText(HTML)

References(25)

References

[1]	Noce A,Marrone G,Ottaviani E,et al. Uremic sarcopenia and its possible nutritional approach[J]. Nutrients,2021,13(1):147. doi: 10.3390/nu13010147
[2]	蔡茜,张祖隆. 终末期肾脏病行维持性血液透析患者发生肌少症的相关影响因素分析[J]. 实用临床医药杂志,2023,27(10):84-90. doi: 10.7619/jcmp.20230632
[3]	Wilkinson T J,Miksza J,Yates T,et al. Association of sarcopenia with mortality and end-stage renal disease in those with chronic kidney disease: A UK Biobank study[J]. J Cachexia Sarcopenia Muscle,2021,12(3):586-598. doi: 10.1002/jcsm.12705
[4]	Teraž K,Marusic U,Kalc M,et al. Sarcopenia parameters in active older adults - an eight-year longitudinal study[J]. BMC Public Health,2023,23(1):917. doi: 10.1186/s12889-023-15734-4
[5]	Harvey N C,Orwoll E,Kwok T,et al. Sarcopenia Definitions as predictors of fracture risk independent of FRAX® ,falls,and BMD in the osteoporotic fractures in men (MrOS) study: A Meta-Analysis[J]. J Bone Miner Res,2021,36(7): 1235-1244.
[6]	罗楠,李新伦,陈凤锟,等. 维持性血液透析相关肌肉减少症的患病率及危险因素的横断面调查[J]. 中国血液净化,2021,20(8):536-539,545. doi: 10.3969/j.issn.1671-4091.2021.08.008
[7]	Gadelha A B,Cesari M,Corrêa H L,et al. Effects of pre-dialysis resistance training on sarcopenia,inflammatory profile,and anemia biomarkers in older community-dwelling patients with chronic kidney disease: A randomized controlled trial[J]. Int Urol Nephrol,2021,53(10):2137-2147. doi: 10.1007/s11255-021-02799-6
[8]	Ito S,Nakashima H,Ando K,et al. Association between Low Muscle Mass and Inflammatory Cytokines[J]. Biomed Res Int,2021,27(20):5572-5742.
[9]	Lapauw L,Dupont J,Amini N,et al. Trial in elderly with musculoskeletal problems due to underlying sarcopenia-faeces to unravel the gut and inflammation translationally (TEMPUS-FUGIT): Protocol of a cross-sequential study to explore the gut-muscle axis in the development and treatment of sarcopenia in community-dwelling older adults[J]. BMC Geriatr,2023,23(1):599. doi: 10.1186/s12877-023-04291-5
[10]	沈冬明,严春霞. 慢性肾脏病患者钙磷代谢、NT-proBNP、Cys-C水平与心力衰竭发生的关系[J]. 海南医学,2023,34(12):1762-1765. doi: 10.3969/j.issn.1003-6350.2023.12.021
[11]	Chen L K,Liu L K,Woo J,et al. Sarcopenia in asia: Consensus report of the asian working group for sarcopenia[J]. J Am Med Dir Assoc,2014,15(2):95-101. doi: 10.1016/j.jamda.2013.11.025
[12]	Di Vincenzo O,Marra M,Di Gregorio A,et al. Bioelectrical impedance analysis (BIA) -derived phase angle in sarcopenia: A systematic review[J]. Clin Nutr,2021,40(5):3052-3061. doi: 10.1016/j.clnu.2020.10.048
[13]	马原,吴银银,窦俊凯,等. 5种肌少症评估工具筛查维持性血液透析患者肌少症效果比较[J]. 护理学杂志,2022,37(13):13-16. doi: 10.3870/j.issn.1001-4152.2022.13.013
[14]	杜雯,陈孜瑾,王雪洁,等. 维持性血液透析患者肌少症的患病率及相关影响因素[J]. 中华肾脏病杂志,2021,37(5):407-413. doi: 10.3760/cma.j.cn441217-20200727-00060
[15]	Ridker P M,Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 therapeutics in cardiovascular disease[J]. Circ Res,2021,128(11):1728-1746. doi: 10.1161/CIRCRESAHA.121.319077
[16]	Hailemichael Y,Johnson D H,Abdel-Wahab N,et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity[J]. Cancer Cell,2022,40(5):509-523. doi: 10.1016/j.ccell.2022.04.004
[17]	Kaizu Y,Ohkawa S,Odamaki M,et al. Association between inflammatory mediators and muscle mass in long-term hemodialysis patients[J]. Am J Kidney Dis,2003,42(2):295-302. doi: 10.1016/S0272-6386(03)00654-1
[18]	Jang D I,Lee A H,Shin H Y,et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics[J]. Int J Mol Sci,2021,22(5):2719. doi: 10.3390/ijms22052719
[19]	He S D,Zhang L,Yu S Y,et al. Association between tumor necrosis factor-alpha(TNF-a) polymorphisms and Schizophrenia: An updated meta-analysis[J]. Int J Psychiatry Clin Pract,2022,26(3):294-302. doi: 10.1080/13651501.2021.2009879
[20]	丁捷,刘红娇,黄鑫,等. 维持性血液透析患者肌少症发病的临床表现及与TNF-α基因多态性的关系研究[J]. 中国中西医结合肾病杂志,2021,22(8):725-727. doi: 10.3969/j.issn.1009-587X.2021.08.023
[21]	Abe K,Yano T,Katano S,et al. Utility of the sarcopenia index for assessment of muscle mass and nutritional status in patients with chronic heart failure: Comparison with anthropometric parameters[J]Geriatr Gerontol Int,2020,20(4): 388-389.
[22]	贾晨,高俊瑞,王鹤宏. 胱抑素C对维持性血液透析患者肌肉减少症的预测价值分析[J]. 中国中西医结合肾病杂志,2021,22(8):709-711. doi: 10.3969/j.issn.1009-587X.2021.08.017
[23]	Hirai K,Tanaka A,Homma T,et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease[J]Clin Nutr,2021,40(3): 1274-1280.
[24]	邓巧妮,王军焕,何家财. 不同活动度过敏性紫癜性肾炎患儿血清cysC、IL-6、TNF-α水平比较[J]. 医学临床研究,2022,39(11):1756-1758. doi: 10.3969/ji.ssn.1671-7171.2022.11.047
[25]	王亚美,刘风勋,邢利,等. Irisin与维持性血液透析患者肌肉减少症的相关性研究[J]. 中国血液净化,2019,18(10):677-680. doi: 10.3969/j.issn.1671-4091.2019.10.005

Relative Articles(20)

Relative Articles

[1]	Kun ZHAO, Yun XIAO, Chun YANG, Zhiling YAN, Minna DONG, Bingquan XIANG, Mingyao XIAO. Protective Effect of Interleukin-4 in Lipopolysaccharide-induced Acute Lung Injury Models. Journal of Kunming Medical University, 2022, 43(8): 41-46. doi: 10.12259/j.issn.2095-610X.S20220805
[2]	Xian ZHANG, Lin ZHAO, Yan-hong LI, Jun-tao ZHANG, Meng-ru ZHAO. Application Value of IL-6, NES and Neonatal Craniocerebral UltrasoundIn Early Diagnosis of White Matter Injury in Premature Infants. Journal of Kunming Medical University, 2021, 42(3): 115-120. doi: 10.12259/j.issn.2095-610X.S20210329
[3]	Yi ZENG, Yun-juan LIAO, Ying LI, Zhen-kun HE. Efficacy of Dapagliflozin on Early Diabetic Nephropathy and Its Effect on Serum MCP-1 and IL-6. Journal of Kunming Medical University, 2021, 42(12): 41-46. doi: 10.12259/j.issn.2095-610X.S20211218
[4]	Qian ZHAO, Xia HE, Ya LING, Rao-yang KE, Sai-nan LI, Rong HUANG, Wen-jin QI. The Clinical Value of Detection of TNF-α、IL-6 and IL-17 in Premature Ruptureof Membranes with Adverse Pregnancy Outcomes Associated with Maternal and Fetal Infection. Journal of Kunming Medical University, 2021, 42(9): 101-107. doi: 10.12259/j.issn.2095-610X.S20210940
[5]	Li ZHANG, Dan YU, Yu-ting WANG, Zhi-mei GOU, Ren-hua YANG, Bo HE, Zhi-qiang SHEN, Wen-ying CHAI, Peng CHEN. Effects of Scutellarin on Expressions of PKC and TNF-α in OX-LDL Injured RAW264.7 Cells in vitro. Journal of Kunming Medical University, 2021, 42(10): 1-7. doi: 10.12259/j.issn.2095-610X.S20211040
[6]	Zeng Yi , Yang Min , Liao Yun Juan , He Zhen Kun , Lian Xi Yan . . Journal of Kunming Medical University, 2019, 40(07): 96-99.
[7]	Zhang He Yun , Zhong Yi Ming , Li Jian , Li Hui , Zheng Ying , Xiong Jie , Wang Ying Bao , Ping Qin Rong , Yang Yang . . Journal of Kunming Medical University, 2018, 39(12): 61-64.
[8]	Bai Run Ai . . Journal of Kunming Medical University,
[9]	Huang Ke Bing . . Journal of Kunming Medical University,
[10]	A Yong Jun . . Journal of Kunming Medical University,
[11]	Ma Wei Jiang . . Journal of Kunming Medical University,
[12]	Ma Cheng Bin . . Journal of Kunming Medical University,
[13]	Liu Ju Peng . . Journal of Kunming Medical University,
[14]	Du Xing Hua . . Journal of Kunming Medical University,
[15]	Zhang Li Ya . . Journal of Kunming Medical University,
[16]	Yao Na . . Journal of Kunming Medical University,
[17]	Zhu Li Rong . . Journal of Kunming Medical University,
[18]	Di Yu Qiang . . Journal of Kunming Medical University,
[19]	Xu Ying . . Journal of Kunming Medical University,
[20]	Tan Lin . . Journal of Kunming Medical University,